Replies to post #63598 on Biotech Values

[DewDiligence]

>Patent '893 is for racemic mixture of Lipitor which expires on March 2010. However, another patent, covering Lipitor (995) enantiomeric salt, expires in May 2011. Even though court ruled against PFE on '995 patent, I think they are fighting on this and now the settlement happened.<

Teva is litigating the ‘995 patent. But even if Teva were to prevail, they would have to contend with Ranbaxy’s FtF 180-day exclusivity.

Moreover, even if Teva were somehow able to get the FDA to rule that the 180-day exclusivity clock begins on expiration of the ‘995 patent, the 180 days would run past the time when Ranbaxy is able to launch under the settlement.

Thus, from PFE’s perspective, there is no risk of a launch by anybody coming sooner than the Nov 2011 date in the settlement.



Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”